Merck Essentially Options A Pipeline In Collaboration With NGM

The big pharma gets one preclinical candidate for cardio-metabolic indications now and options to virtually everything else in the biotech’s pipeline. NGM receives $94 million up front, $250 million in R&D funding over five years and a $106 million equity investment.